Redcliffe Labs has appointed Kshitiz Singh as Chief Business Officer – Inorganic Growth, as the diagnostics company looks to accelerate its expansion through strategic partnerships and acquisitions.
Singh joins Redcliffe Labs with more than 26 years of experience spanning diagnostics, healthcare, pharmaceuticals and FMCG. His expertise includes sales leadership, business development and commercial strategy.
Prior to joining Redcliffe Labs, Singh served as General Manager and Business Head at Agilus Diagnostics. During his career, he has also held leadership positions at Piramal Enterprises, Abbott India, Heinz India, Sanofi, AstraZeneca and GlaxoSmithKline.
Commenting on the appointment, Aditya Kandoi, Founder and CEO of Redcliffe Labs, said the diagnostics industry is entering a phase where scale, integration and regional reach will be critical to long-term growth.
"Across the country, several strong regional diagnostic businesses have built deep clinical expertise and patient trust. We see a significant opportunity to bring these strengths together through an integrated platform that combines technology, clinical excellence and preventive healthcare. Kshitiz's experience across diagnostics and healthcare will help us accelerate this journey while strengthening our presence across regional markets," Kandoi said.
Speaking on his new role, Kshitiz Singh said India's diagnostics sector offers significant opportunities to strengthen healthcare through strategic partnerships and capability building.
"Redcliffe Labs has built a strong foundation for preventive care driven by its commitment and a clear purpose of adding healthy years to lives. I look forward to working with the leadership to identify growth opportunities, forge strong partnerships and strengthen our network to bring trusted, high-quality diagnostics to more people across the country," Singh said.
In his new role, Singh will lead Redcliffe Labs' inorganic growth initiatives, with a focus on expanding the company's footprint and strengthening its position in India's diagnostics market through strategic collaborations and acquisitions.
